Condition: Pancreatic Cancers · Pancreatic Diseases · Sponsor: Do Hyun Park
Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.
This description comes directly from the study's public registry record.
HyeJin Song, CRC · +82-2-2045-3825 · asangicrc@gmail.com
Always discuss trial participation with your own doctor first.
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07030348